CASI Pharmaceuticals, Inc (DE) Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q1 2021 to Q3 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
CASI Pharmaceuticals, Inc (DE) quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q1 2021 to Q3 2022.
- CASI Pharmaceuticals, Inc (DE) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2022 was -$5.02M, a 49.9% increase year-over-year.
- CASI Pharmaceuticals, Inc (DE) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2022 was -$26.3M.
- CASI Pharmaceuticals, Inc (DE) annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$35.8M, a 24.6% increase from 2020.
- CASI Pharmaceuticals, Inc (DE) annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$47.5M.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)